Jack Bendheim Sells 5,280 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,280 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $48.91, for a total value of $258,244.80. Following the sale, the chief executive officer directly owned 96,200 shares in the company, valued at $4,705,142. This trade represents a 5.20% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total transaction of $400,600.20.

Phibro Animal Health Stock Up 2.6%

PAHC opened at $52.51 on Wednesday. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $56.30. The firm has a market capitalization of $2.13 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 0.79 and a beta of 0.74. The company has a fifty day moving average price of $46.83 and a 200-day moving average price of $42.51.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio (DPR) is 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds have recently added to or reduced their stakes in the company. Penserra Capital Management LLC bought a new position in Phibro Animal Health during the third quarter valued at approximately $519,000. Capricorn Fund Managers Ltd bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth approximately $10,233,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth approximately $8,931,000. Bailard Inc. purchased a new stake in shares of Phibro Animal Health in the 2nd quarter valued at $259,000. Finally, Citigroup Inc. boosted its stake in shares of Phibro Animal Health by 112.3% in the 3rd quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock valued at $2,223,000 after purchasing an additional 29,066 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Wall Street Analyst Weigh In

PAHC has been the topic of several research analyst reports. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.